noodls browser compatibility check

The security settings of your browser are blocking the execution of scripts.

To use noodls, javascript support must be enabled. Please change your browser's security settings to enable javascript.

If you have changed your browser's security settings, you can click here.

related announcements

News

Peakequity Partners Management Co LLC

PeakEquity Partners Successfully Exits G5
Peakequity Partners Management Co LLC

Thoma Bravo Completes Strategic Investment in PeakEquity Portfolio[...]
Peakequity Partners Management Co LLC

HighLevel Announces Minority Growth Investment from General Atlantic

Healthcare

Pappas Capital LLC

09/28/2015 | Press release | Archived content

Afferent Pharmaceuticals Announces Positive Results in Phase 2b C...

News | 09. 28. 2015

Afferent Pharmaceuticals

SAN MATEO, Calif - September 28, 2015 - Afferent Pharmaceuticals, a leader in the development of small molecule compounds targeting P2X3 for the treatment of poorly managed and common neurogenic disorders, such as chronic cough, today announced positive top-line results from its Phase 2b dose escalation clinical trial of AF-219 in chronic cough patients. AF-219 is a selective, non-narcotic and orally administered P2X3 antagonist that targets the mechanism by which certain nerve fibers become hyper-sensitized and can lead to chronic and debilitating symptoms. The results of this clinical trial will be presented at a scientific meeting in the future.

Pappas Capital LLC published this content on September 28, 2015, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on April 22, 2026 at 10:00 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]

Back

View original format